Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56599 | 0.88 | ALDH1A1 (0.65) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL10051059 | 0.88 | CA1 (0.55) | ALDH1A1HSD17B10CA1CA2LOXL2 | |
| SCHEMBL2264686 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL14120843 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HSD17B10TDP1ENPP2SMN1; SMN2 | |
| SCHEMBL1156456 | 0.78 | PSIP1 (0.56) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL30595316 | 0.77 | CA2 (0.77) | CA1CA2LOXL2LOXLMNA | |
| SCHEMBL4573877 | 0.77 | CA1 (0.44) | ALDH1A1HSD17B10CA1CA2LOXL2 | |
| SCHEMBL4573879 | 0.77 | CA2 (0.77) | CA1CA2LOXL2LOXLMNA | |
| SCHEMBL31281283 | 0.77 | PGR (0.52) | ALDH1A1TDP1MEN1KMT2ALMNA | |
| SCHEMBL18948539 | 0.77 | CA1 (0.44) | ALDH1A1HSD17B10CA1CA2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | THE UNIVERSITY OF NOTTINGHAM (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| US-12186301-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240066002-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11786501-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-08-17 | — | — | US | disclosed |
| CN-115286542-B | Preparation method of sulfinate compound | 浙江工业大学 | 2023-08-15 | — | — | CN | disclosed |
| US-6638931-B1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786501-B2 | Nitroxyl donors with improved therapeutic index | TNNI3, TNNT2, TNNC1 | ALDH1A1 1005/4885HSD17B10 442/4885TDP1 591/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | ALDH1A1 68/4885HSD17B10 3838/4885TDP1 4306/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | ALDH1A1 4067/4885HSD17B10 3996/4885TDP1 2895/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | ALDH1A1 2867/4885HSD17B10 3924/4885TDP1 835/4885 |
| US-12186301-B2 | Nitroxyl donors with improved therapeutic index | TNNI3, TNNT2, TNNC1 | ALDH1A1 1005/4885HSD17B10 442/4885TDP1 591/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | ALDH1A1 3151/4885HSD17B10 3984/4885TDP1 881/4885 |
| US-20240066002-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | ALDH1A1 1005/4885HSD17B10 442/4885TDP1 591/4885 |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | ITGA2, ITGB2, ITGB1 | ALDH1A1 814/4885HSD17B10 3114/4885TDP1 4504/4885 |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | ITGA6, ITGA1, ITGA2 | ALDH1A1 579/4885HSD17B10 3249/4885TDP1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.